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9 Abstract
10 Background Despite the widespread availability of bio-
11 logical drugs in psoriasis, there is a shortage of disease
12 burden studies.
13 Objectives To assess the cost-of-illness and quality of
14 life of patients with moderate to severe psoriasis in
15 Hungary.
16 Methods Consecutive patients with Psoriasis Area and
17 Severity Index (PASI) [ 10 and Dermatology Life Quality
18 Index (DLQI) [ 10, or treated with traditional systemic
19 (TST) or biological systemic treatment (BST) were inclu-
20 ded. Demographic data, clinical characteristics, psoriasis
21 related medication, health care utilizations and employ-
22 ment status in the previous 12 months were recorded.
23 Costing was performed from the societal perspective
24 applying the human capital approach. Quality of life was
25 assessed using DLQI and EQ-5D measures.
26 Results Two-hundred patients were involved (females
27 32 %) with a mean age of 51 (SD 13) years, 103 (52 %)
28 patients were on BST. Mean PASI, DLQI and EQ-5D
29 scores were 8 (SD 10), 6 (SD 7) and 0.69 (SD 0.3),
30 respectively. The mean total cost was €9,254/patient/year
31(SD 8,502) with direct costs accounting for 86 %. The
32main cost driver was BST (mean €7,339/patient/year).
33Total costs differed significantly across treatment sub-
34groups, mean (SD): no systemic therapy €2,186 (4,165),
35TST €2,388 (4,106) and BST €15,790 (6,016) (p \ 0,001).
36Patients with BST had better PASI and DLQI scores
37(p \ 0.01) than the other two subgroups.
38Conclusions Patients with biological treatment have a
39significantly better quality of life and higher total costs than
40patients with or without traditional systemic treatment. Our
41study is the largest in Europe and the first in the CEE
42region that provides cost-of-illness data in psoriasis
43involving patients with BST. 4




49Psoriasis is a chronic inflammatory condition affecting
50about 0.73 to 2.9 % of the population in Europe [1]. Skin
51disease with multiple different phenotypic variations and
52degrees of severity is the most prominent feature of
53psoriasis. Approximately 80 % of patients with psoriasis
54have mild to moderate disease, whereas 20 % have
55moderate to severe disease [2]. Classification of psoriasis
56severity takes into account not only the extent of body
57surface area involvement, but also the intensity of local
58signs and symptoms, history of previous treatments, dis-
59ease duration, degree of disability and the impact of the
60disease on patients’ quality of life [3]. Even a mild disease
61with limited extent can have a substantial psychological
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62 impact on one’s personal well-being [4]. Psoriasis is
63 associated with considerable co-morbid conditions and
64 elevated mortality has been observed in severe psoriasis
65 [5, 6]. Epidemiological studies suggest that about 5–25 %
66 of patients with psoriasis also develop psoriatic arthritis
67 (PsA) [7].
68 While commonly considered a non-life-threatening
69 disease, psoriasis represents significant social and financial
70 burden both for patients and the healthcare system. Owing
71 to the persistent character of the disease patients with
72 psoriasis usually need lifelong care which generates high
73 continuing costs [8].
74 Highly effective and expensive biological therapies have
75 increased interest in the cost-of-illness (COI) associated
76 with psoriasis. A systematic literature review on the disease
77 burden of moderate to severe psoriasis was published by
78 Raho et al. [9] covering the period between 2002 and 2010.
79 They found altogether seven COI studies from five coun-
80 tries (2 USA, 2 Germany, 1-1 Italy, Spain and Switzer-
81 land). Authors highlighted that patients’ health related
82 quality of life (HRQL) was affected by psoriasis to a
83 degree comparable with diabetes or cancer. Treatment
84 costs varied significantly across the studies. Direct costs
85 were higher than indirect costs with hospitalization repre-
86 senting the most significant item. It is important to note,
87 however, that there were no patient samples with biological
88 treatment among the seven COI studies and none were
89 from the Central and Eastern European (CEE) region.
90 The objective of our study was, therefore, to evaluate
91 the disease burden of moderate to severe psoriasis in
92 Hungary by assessing disease related costs from a societal
93 perspective and patients’ HRQL. Moreover, we updated the
94 literature search for psoriasis COI studies in order to place
95 our results in the context of the available publications.
96 These data are required for health economic analyses and
97 can provide a more complete picture to health care pro-
98 viders and policy makers on the economic implications of
99 the disease.
100 Detailed analysis of HRQL related findings, including
101 the mapping of EQ-5D utilities on disease-specific mea-
102 sures, are provided in another article in this supplement
103 [10]. In this paper we present the main HRQL data and
104 focus on COI results. Besides reporting summary results,
105 we provide subgroup analyses in order to give an insight
106 into the clinical and economic impact of different treat-
107 ments. Thus, three subgroups were created after sampling
108 based on patients’ psoriasis treatment at the time of the
109 survey: patients not receiving systemic therapy (NST);
110 patients receiving traditional systemic treatment (TST)
111 such as methotrexate, retinoids, cyclosporine or photo-
112 therapy; and patients on biological systemic treatment
113 (BST), namely on adalimumab, etanercept, infliximab or
114 ustekinumab.
115Methods
116Study design and patients
117We conducted a non-interventional, cross-sectional ques-
118tionnaire survey in two university dermatology clinics in
119Hungary. Patients with diagnosis of psoriasis, aged C18 -
120years and who gave informed consent were consecutively
121enrolled between September 2012 and May 2013. Inclusion
122criteria were set up considering disease severity (assessed
123by the Psoriasis Area and Severity Index, PASI), health
124related quality of life (assessed by the Dermatology Life
125Quality Index, DLQI) and treatment history [11]. (PASI
126and DLQI are introduced in the next section). Patients were
127eligible for inclusion with either 1) PASI [ 10 and
128DLQI [ 10; or 2), traditional systemic treatment (TST) or
129biological systemic treatment (BST) at the time of the
130survey. Ethical approval was obtained from the national
131ethical committee (ETT-TUKEB 35183/2012-EKU).
132Survey
133Patients completed a set of questions in which demo-
134graphic data, employment status, disease duration, self-
135assessed disease activity on a visual analogue scale (VAS)
136and psoriasis related topical treatments were surveyed.
137Psoriasis related outpatient care utilizations (GP and der-
138matologist visits in the past one and three months,
139respectively), hospitalizations and transportation to attend
140medical care in the previous 12 months were recorded.
141Informal care was assessed for the past month (the number
142of hours per week provided by others to help the patient in
143his/her everyday activities). Patients were asked to indicate
144co-payments and full out-of-pocket expenditures as well.
145Absence from work and reduced work productivity were
146captured by the Work Productivity and Activity Impair-
147ment questionnaire (WPAI) [12].
148A validated Hungarian version of the Dermatology Life
149Quality Index (DLQI) was used to assess disease-specific
150quality of life. The DLQI ranges between 0 (not affected)
151to 30 (extremely affected), the higher scores correspond to
152a more impaired quality of life [13].
153As a generic health status measure, the EQ-5D question-
154naire was used which comprises a descriptive system (EQ-
1555D-3L) and a Visual Analogue Scale (EQ VAS). The
156responses to the EQ-5D-3L were converted to utility scores
157(ranging from -0.594 to 1.0) using the UK social tariffs [14].
158Participating dermatologists assessed disease activity on
159a VAS and disease severity by the Psoriasis Area and
160Severity Index (PASI) [15]. The PASI combines assess-
161ments of the extent of body surface involvement in four
162anatomical regions (head, trunk, arms and legs) and the
163severity of desquamation, erythema and plaque induration
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164 (thickness) in each region, yielding an overall score from 0
165 to 72. The PASI is part of most currently used classifica-
166 tions of disease severity in psoriasis and represents a nec-
167 essary first step in selecting a treatment strategy. Moderate
168 to severe disease is defined as a PASI score [10 [15].
169 Dermatologists categorized patients by the clinical features
170 of psoriasis and provided data on current and previous
171 systemic treatments (both traditional and biological sys-
172 temic treatments in the past 12 months).
173 Costs calculation
174 Data obtained from the questionnaire survey were used for
175 the calculation of psoriasis related costs. Cost calculation
176 was performed from a societal perspective (including direct
177 medical, direct non-medical and indirect costs) over a
178 12-months period. Hungarian official prices and tariffs were
179 used and costs were presented in 2012 EUR rate (€1 = 285
180 HUF). The cost of outpatient care was calculated by multi-
181 plying the number of visits by the estimated unit prices (GP:
182 €5.2/visit, specialist: €5.7/visit) [16, 17]. Cost of hospital-
183 ization was based on Disease Related Groups (DRGs)
184 reimbursement list (€373.7/admission) [18]. Drug costs were
185 calculated based on official national prices of pharmaceuti-
186 cals [17]. Travel cost to attend health care due to psoriasis
187 was calculated considering the number of visits, the mode of
188 transportation used and the distance between the patient’s
189 residence and the dermatology centre [19, 20]. In cases of
190 ambulance transportation unit costs per km (€3.1/km) was
191 applied based on official financing data [21].Weekly cost of
192 informal care was estimated by multiplying the average
193 hourly net wage in Hungary (€3/hour) [16] with the number
194 of hours per week, but it was capped at a maximum of 40 h/
195 week. The costs of absence from work and disability pension
196 due to psoriasis were calculated using both Human Capital
197Approach (HCA) [22] and Friction Cost Approach (FCA)
198[23] with six-month friction period. Average gross income
199(€1,054/month in 2012, including net wage, personal income
200tax, pension contribution, health insurance contributions,
201employer’s contribution) was used to estimate daily cost
202(€50/day) of productivity loss which was multiplied with the
203number of days of absence [16].
204Statistical analysis
205Statistical analysis of the data was carried out using SPSS
206Version 20.0 for Windows. Descriptive statistics were
207performed and analyses focused on the comparison
208between treatment subgroups (NST, TST, and BST). We
209present the mean with standard deviation, median and
210bootstrap confidence intervals (1,000 drawings) for each
211cost domain. Due to the skewed distribution of the cost
212data, subgroups were compared by non-parametric tests.
213The level of significance was set to 0.05.
214Results
215Socio-demographic and clinical characteristics
216Altogether 200 patients completed the questionnaire, 68 %
217were male. The mean age of the patients was 51 years (SD 13)
218and the disease duration was 22 years (SD 11). Main char-
219acteristics of the patients are presented in Table 1. The dis-
220tance between the patient’s home and the dermatology centre
221was mean 51 (SD 57) km. Altogether 99 (50 %) patients were
222working (fulltime 79, part time 20) at the time of the assess-
223ment, 16 (8 %) were on disability pension due to psoriasis.
224Regarding the characteristics of subgroups, patients receiving
225biological drug (BST subgroup) were significantly younger
Table 1 Main characteristics of
the patients
NST no systemic treatment, TST





NST N = 36;
mean (SD)
TST N = 61;
mean (SD)
BST N = 103;
mean (SD)
Descriptive statistics
Females N (%) 63 (32) 11 (31) 21 (34) 31 (30)
Age (year) 51 (13) 56 (13) 52 (13) 49 (12)
Disease duration (year) 22 (11) 18 (11) 23 (12) 23 (11)
Weight (kg) 88 (18) 83 (15) 86 (20) 91 (18)
Height (cm) 172 (9) 171 (9) 170 (10) 172 (9)
Body Mass Index (BMI) 29.85 (5) 28.38 (6) 29.75 (5) 29.55 (5)
Disease related variables
PASI index 8 (10) 18 (11) 11 (10) 2 (5)
DLQI score 6 (7) 12 (6) 10 (8) 2 (4)
EQ VAS 64 (21) 55 (20) 59 (17) 70 (22)
EQ-5D score (-0.594–1) 0.69 (0.3) 0.65 (0.3) 0.62 (0.3) 0.75 (0.3)
Self-assessed disease activity VAS (0–100 mm) 35 (33) 60 (30) 49 (31) 18 (25)
Physician’s global assessment VAS (0–100 mm) 23 (28) 58 (24) 34 (28) 7 (14)
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226 than patients without systemic treatment (NST) and moreover,
227 disease duration of patients receiving systemic treatment
228 (BST and TST subgroups) had a significantly longer disease
229 duration than NST patients (p \ 0.05).
230 Health care utilizations due to psoriasis
231 Health care utilizations, medications and productivity loss
232 are presented in Table 2. Altogether 105 patients (53 %)
233 have had biological treatment in the past 12 months and
234 seven switches occurred between diverse biological agents
235 whilst two patients stopped biological treatment. Thus,
236 altogether 103 patients (52 %) were on biological treatment
237 at the time of the survey, and they were considered for the
238 BST subgroup. Thirty-six (18 %) patients were in the NST
239 subgroup and 61 patients (30 %) were receiving TST.
240 Psoriasis related costs
241 The annual costs of all psoriasis related items are
242 presented in Table 3. The mean annual total cost per
243patient with HCA and FCA was €9,254 (SD €8,502)
244and €8,305 (SD €7,705), respectively, with direct costs
245accounting for 86 and 96 %. The main cost driver was
246the biological drug cost amounting to mean €7,339/
247patient/year in the total sample (N = 200). Average
248total cost differed significantly between treatment sub-
249groups (NST, TST and BST) both with HCA and FCA
250(p \ 0.001) (Table 3).
251Disease severity and quality of life across treatment
252subgroups
253Disease severity (PASI) differed significantly across the
254three subgroups as patients without systemic treatment
255(NST) were in the worst state whilst those on biological
256drug (BST) in the best state (p \ 0.01). HRQL (assessed by
257the DLQI) of patients with biological treatment was sig-
258nificantly better compared to the other two subgroups
259(p \ 0.01). The difference in health status utility (EQ-5D
260score) was significant only between BST and TST sub-
261groups (p \ 0.01) (Table 1).
Table 2 Annual utilization of health care services, drugs and productivity loss














GP visits 49 (25) 4.3 12 (33) 6.6 26 (43) 7.5 11 (11) 1.5
Dermatology specialist visit 159 (80) 6.3 24 (67) 9.5 49 (80) 7.6 86 (84) 4.5
Dermatological inpatient care 57 (29) 0.4 11 (31) 0.4 32 (53) 0.6 14 (14) 0.2
Transportationa
Ambulance 10 (5) 0.2 – – 3 (5) 0.4 7 (7) 0.3
Travel voucher 28 (14) 0.6 1 (3) 0.05 9 (15) 0.5 18 (18) 0.8
Travel cost 172 (86) 1.7 35 (97) 2.6 52 (85) 2.3 85 (83) 1
Productivity lossb
Sick leave 18 (9) 2 4 (11) 1.4 8 (13) 3.6 6 (6) 1.3
Disability due to psoriasis 16 (8) 29 3 (8) 30 2 (3) 12 11 (11) 39
Pharmacotherapyc
TST
Methotrexate 86 (43) 226 7 (19) 136 38 (62) 216 41 (40) 252
Retinoids 22 (11) 151 4 (11) 151 16 (26) 164 2 (2) 47
Cyclosporin 16 (8) 189 3 (1) 233 10 (16) 223 3 (3) 30
Phototherapy 7 (4) 77 2 (1) 188 5 (8) 32 – –
BST
Etanercept 18 (9) 293 – – – – 18 (17) 293
Infliximab 42 (21) 319 – – – – 42 (40) 319
Adalimumab 35 (18) 300 – – 1 (2) 21 34 (33) 308
Ustekinumab 17 (9) 260 – – 1 (2) 176 16 (16) 265
a Utilization of health care services for the total group
b The length of absence or disability (days)
c Drug utilization among active users of the given medication in the past 12 months (days of treatment)
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263 This study provides data on COI and HRQL in patients
264 with moderate to severe psoriasis in Hungary attending
265 hospital based dermatology centres. The annual societal
266 cost of psoriasis in patients with a mean age of 50 years
267 and a disease duration since first medical diagnosis of
268 psoriasis of 22 years is mean €9,254 per patient, and is
269 primarily driven (86 %) by direct medical costs.
270 The majority of the patients (N = 103, 52 %) were
271 receiving a biological agent at the time of the assessment.
272 According to the latest available data of National Health
273 Insurance Fund Administration, in 2010 altogether 682
274 patients with psoriasis received biological treatment in Hun-
275 gary thus our survey captured a substantial proportion of this
276 patient group [24]. Analysis by treatment subgroups revealed
277 that yearly average total costs differ significantly across NST
278 (€2,186), TST (€2,388) and BST (€15,790) subsamples.
279 Significant differences were observed across treatment
280 subgroups with regard to disease severity (PASI, DLQI)
281 and patients’ general health state (EQ-5D) as well
282 (Table 1). Patients with biological treatment had a signif-
283 icantly lower disease severity (PASI score) and better
284 HRQL (DLQI score) than their counterparts with or with-
285 out traditional systemic treatment. The EQ-5D indicated
286 also the best health state in the BST subgroup, however, the
287 difference was significant only compared to the TST sub-
288 group. When comparing EQ-5D utility weights to the age-
289 matched population norm in Hungary (age group
290 45–54 years, mean 0.81) [25] a lower average score was
291 observed in each subgroup (NST: 0.65, TST: 0.62, and
292 BST: 0.75) resulting in a difference of 0.16, 0.19 and 0.6,
293 respectively.
294 Both the average direct medical cost (excluding bio-
295 logical treatment costs) and indirect cost were the lowest in
296 the BST subgroup when applying the 6-month FCA
297 (Table 3). One reason for that is the rate of patients who
298 went on sick leave due to psoriasis in the past 12 months
299 was the lowest (6 %) among the subgroup of patients with
300 biological treatment (Table 2). On the other hand, although
301 the rate of disability pensioners was the highest in this
302 same subsample (11 %), all of them were classified as
303 permanently unable to work before the time period con-
304 sidered for the friction cost calculation. As a consequence,
305 when HCA was used to calculate productivity related costs,
306 the BST subgroup ranked as the one with the highest
307 indirect cost. Overall we can conclude that patients on
308 biological treatment had the highest total costs but the
309 lowest disease activity and best quality of life compared to
310 their counterparts receiving conventional systemic treat-
311 ment or no systemic treatment.
312 Presence of psoriatic arthritis (PsA) may represent
313 additional burden in psoriasis although findings in the
314literature are contradictory [26]. In our study 57 patients
315(29 %) were diagnosed with PsA (females 35 %, mean age
31654 years, psoriasis disease duration 23 years) and 52 % of
317them received biological therapy. The mean EQ-5D score
318of patients with concomitant PsA was significantly lower
319(\0.01) than that of patients without PsA, nevertheless they
320were older as well (54 vs. 51 years, p = 0.035). Cost of
321informal care was high (mean €314/patient/year) among
322PsA patients reflecting a high disability and dependence on
323others of this specific subsample. Mean annual cost (with
324HCA) of patients with PsA was €8,977 (SD 9,488) per
325patient and total costs by NST, TST and BST subgroups
326were mean €1,729, €775 and €16,983, respectively. For
327comparison, Brodszky and colleagues surveyed 183
328patients with PsA in Hungary in 2007 with similar age
329(mean 50 years) and disease duration (mean 19 years) [27].
330The rate of patients on biological treatment was much
331lower (6 %) resulting in a somewhat lower total cost (mean
332€5,547/patient/year, on 2007 prices). Nevertheless, when
333patients on biological treatment were excluded from the
334analysis total cost were much higher (mean €4,281/patient/
335year, on 2007 prices) than in the NST and TST subgroups
336of PsA patients in our current survey. These results seem to
337suggest that rheumatic features might add extra HRQL loss
338and increase in costs in psoriasis. Nonetheless, further
339direct comparative studies are needed to confirm our
340findings.
341Taking into account that the first biological agent was
342registered for the treatment of psoriasis in 2004, we would
343have expected COI studies involving patients with bio-
344logical treatment by the end of January 2010, the date when
345the last systematic literature review was closed [9]. Con-
346trarily, no such studies had been published by that time.
347Therefore, we performed a literature search for COI studies
348for the period from January 2010 to December 2013 using
349the same search terms and databases as Raho et al. [9].Our
350search identified a further nine publications [28–36], seven
351of which involved psoriasis patients with biological treat-
352ment. In the COI analyses conducted by Fonia et al. (UK)
353[28] and Driessen et al. (the Netherlands) [29] all patients
354were treated with biological drugs. The biological treat-
355ment rate was 16 % in the study by Ghatnekar et al.
356(Sweden) [34], 13 % by Levy and colleagues (Canada)
357[33], 6 % by Steinke et al. (Germany) [36] and 3.6 % by Le
358Moigne et al. (France) [32]. Only one study by Gleason and
359colleagues (US) did not report the rate of biological therapy
360[31].
361Studies that provided costs specifically for BST groups
362or subgroups were selected for comparison. Neither the
363study by Gleason et al. (US) [31] nor the one by Levy et al.
364(Canada) [33] reported costs data for BST group, therefore,
365these were excluded. Moreover, only eight patients
366received biological agent in the study by Steinke et al. [36]
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367 (Germany) so this was not considered either. Finally we
368 compared our results to four studies: Fonia (UK, 2010)
369 [28], Driessen (the Netherlands, 2010) [29], Ghatnekar
370 (Sweden, 2012) [34] and Le Moigne (France, 2013) [32]
371 (Table 4).
372 Fonia et al. [28] conducted a retrospective chart review
373 involving 76 BST patients. Health care resource utilization
374 data were collected 12 months before and after BST initi-
375 ation. The viewpoint of cost calculation was the third party
376 payer and only direct medical costs were collected. Total
377 cost of psoriasis care prior to biological treatment was
378 £4,207/patient/year (€4,742) while after the biological
379 treatment was initiated total costs rose to £11,981/patient/
380 year (€13,505). The cost of the biological treatment was the
381 main cost driver. However the total cost of hospitalization
382 decreased by £1,683/patient/year (€1,897) and PASI
383 decreased by 8.9 points in the BST subgroup.
384 A similar study design was applied in the Netherlands.
385 Driessen et al. [29] collected health care resource utiliza-
386 tion data 12 months before and after starting biologic
387 therapy start based on retrospective chart review including
388 67 BST patients. Mean direct medical cost during the pre
389 and post period was €10,146 and €17,712/patient/year,
390 respectively. The costs of other drug treatments, outpatient
391 visits and hospitalizations decreased during the year after
392 the biological therapy was given. An improvement of skin
393 manifestation was observed after BST initiation and PASI
394 decreased by 12.6 points.
395A retrospective health insurance claims database ana-
396lysis was conducted by Le Moigne et al. [32] among
397patients with moderate to severe psoriasis in France. Two
398cohorts of 69 BST and 1,855 TST patients were compared
399during a 6-month period. The mean total direct medical
400costs in BST and TST patient groups were €16,214 vs.
401€3,356/patient/year. All cost items were higher in the BST
402subgroup and the largest difference was identified in the
403cost of hospitalization, as this cost item was €886/patient/
404year higher than in TST subgroup.
405In Sweden, Ghatnekar et al. [34] performed a 1-month
406prospective study in 2009 from the societal viewpoint.
407Altogether 164 patients were involved and among them 27
408(16 %) patients received BST. For the whole study popu-
409lation the average total cost was €11,928/patient/year
410(when monthly costs are multiplied by 12) which is higher
411than in our study (€9,254/patient/year). The total cost of
412TST subgroup was €13,020/patient/year, which is much
413higher than our TST result (€2,388/patient/year).
414The main direct cost drivers were the biological drugs,
415outpatient visits and phototherapy. The indirect cost (pro-
416ductivity loss) was 16 % of the total costs, which is similar
417to our finding of 14 % associated with indirect costs. In the
418BST subgroup the yearly average total costs were €20,508
419whilst we reported €15,790 per patient in our study. The
420indirect costs were lower in BST than in the TST subgroup
421(€2,051 vs. €5,208). Despite the €14,280/patient/year dif-
422ference of drug costs for TST vs. BST, the difference in
Table 4 Cost-of-illness studies of psoriasis, reporting costs of BST, till December 2013 in comparison with results of the current survey















































General psoriasis population, all types of




















n.r. not reported, n.a. not applicable
Levy and colleagues did not report costs of BST population, Steinke and colleagues reported costs of BST population, however, the sample size
of the patients treated with biologicals were low (N = 8), not big enough for comparison
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423 total cost between these two subgroups was only €7,476/
424 patient/year due to the offsets from improved productivity.
425 In our study the indirect cost of BST subgroup was higher
426 (HCA) than in TST subgroup (€1,427 vs. €960).
427 The total costs of BST presented in three of the four
428 studies [29, 32, 34] were higher compared to our results
429 in Hungary. In three studies [28, 29, 32] the costs of
430 hospitalization and out-patient visits were lower in BST
431 subgroup, similarly to our findings. These studies were
432 conducted in tertiary dermatology centres with a very
433 similar methodology. Le Moigne et al. [32] presented
434 different results. In this study the cost of out-patient visit
435 and hospitalization was higher in the BST subgroup
436 compared to other subgroups. Health care utilization data
437 are greater depending on the financing mechanisms,
438 professional and financing guidelines, management,
439 standard care, referral system, unit costs and cost
440 accounting approaches of the given country and vary
441 substantially, so it is very difficult to make comparisons
442 among countries.
443 Our study has some limitations. The survey was con-
444 ducted in two university based dermatology centres
445 involving psoriasis patients attending outpatient care.
446 Patients with mild psoriasis were not selected and patients
447 with severe psoriasis might be under-represented in the
448 sample. We used a retrospective survey to assess health
449 care utilizations, recall bias might occur. Another limita-
450 tion is due to the cross-sectional design, the current treat-
451 ment were used as a proxy to measure disease severity and
452 costs. In this sample there is a mixed patient population in
453 terms of severity of disease, patients with recently initiated
454 or changed treatment where the full effect has not been
455 achieved yet. Seasonal variations were not taken into
456 consideration. Further research is needed involving repre-
457 sentative samples and incidence follow-up cohorts to fur-
458 ther assess the changes in costs and in quality of life in the
459 long term.
460 Our study showed that the economic burden of psoriasis
461 is considerable in Hungary and revealed that results from
462 health economic studies in psoriasis in other countries
463 cannot be adapted without adjustment. With this study we
464 provided input for further health economic analyses and a
465 baseline to evaluate the economic effects of psoriasis
466 treatment in Hungary. In line with our hypothesis, bio-
467 logical treatment increased the direct costs associated with
468 psoriasis while considerably improving the quality of life
469 of patients. Our study was the first from the CEE region
470 that provided COI data and had the largest sample size of
471 biologic treated patients in Europe.
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